Drugs / Lopinavir/Ritonavir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00344487 | Dec 2005 → May 2009 | HIV infectious disease | University of Maryland, Baltimore | Terminated | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-02-07 | AbbVie | Regulatory AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results abbvie.com ↗
The application is being reviewed under the FDA's Real-Time Oncology Review pilot program and is based on results from the Phase 3 E1912 study, which showed significantly improved PFS and overall survival (OS) in patients treated with IMBRUVICA plus rituximab compared to those treated with fludarabine, cyclophosphamide and rituximab (FCR). |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
| 2020-02-07 | AbbVie | AbbVie Reports Full-Year and Fourth-Quarter 2019 Financial Results abbvie.com ↗ |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/Ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00344487 ↗ |
| Known as | Kaletra | “The dose of lopinavir/ritonavir (Kaletra) for this study will be 400/100mg. BID or 800/200mg. qd.” NCT00344487 ↗ |
| Route | Oral | “lopinavir/ritonavir (Kaletra)400/100mg tablets by mouth twice a day for 48 weeks.” NCT00344487 ↗ |